Clear Street analyst Bill Maughan reiterates a Buy rating and $185 price target on “top pick” for the second half BioNTech (BNTX) after the company announced that its antibody drug conjugate BNT323/DB-1303 beat trastuzumab emtansine on the primary endpoint of progression-free survival in a Phase 3 Chinese study in HER2+ metastatic or unresectable breast cancer run by partner DualityBio. The update “was largely expected” and does not change the firm’s view that BioNTech is building an integrated oncology pipeline based on the next-gen immuno-oncology agent BNT327, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Video: Broadcom up on mystery AI customer, Lululemon sinks as Street downgrades
- Morning Movers: Broadcom up on earnings, unnamed new AI customer
- BioNTech says trastuzumab pamirtecan met primary endpoint in Phase 3 trial
- BioNTech and DualityBio’s Phase 3 Trial Success in Breast Cancer
- FDA vaccine chief overruled scientists on Covid shot access, NY Times reports